Cover Image
市場調查報告書

遺傳基因檢驗的全球市場:產業分析,市場預測

Global Genetic Testing Market - Industry Analysis and Market Forecast (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 319191
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
遺傳基因檢驗的全球市場:產業分析,市場預測 Global Genetic Testing Market - Industry Analysis and Market Forecast (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 205 Pages
簡介

本報告提供全球遺傳基因檢驗市場相關調查分析,市場概要,市場因素,市場區隔考察,各地區分析,競爭情形,主要企業簡介等相關彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 主要影響因素

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 波特的五力分析

第6章 市場成長因素、阻礙成長要素、機會、課題分析

  • 市場發展因素
  • 市場發展阻礙要素
  • 市場機會
  • 市場課題

第7章 遺傳基因檢驗市場分類

  • 各類型
  • 各疾病
  • 各技術
  • 各地區

第8章 競爭情形

  • M&A
  • 協定、競爭、聯盟
  • 新產品的銷售

第9章 企業簡介

第10章 分析師的投資機會預測

第11章 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

The global genetic testing market accounted for USD 3.8 Billion in 2015 and is estimated to reach USD 4.23 billion in 2016. Growing at a moderately high CAGR of 9.7%, the market value is expected to reach USD 6.7 billion by 2021.

Some values in the chart may be randomized. Actual data available on report purchase

In the recent years, with advancements in science and technology, genetic testing has grown to become one of the most important markets in healthcare. Genetic testing allows diagnosis of a disease after its onset, as well as predicting the risk of acquiring a certain disease. There are a number of government initiatives that are being taken to bring about awareness and educate people about the benefits of genetic testing.

Global Genetic Testing Market- Market Segmentation

The global genetic testing market is segmented by type, disease, technology and geography.

By type, the market is segmented into carrier testing, diagnostic testing, new-born screening, predictive & pre-symptomatic testing and prenatal testing.

The new-born screening market accounted for the highest market share in 2015 and is projected to reach USD XX million in 2016 and USD XX billion by 2021, at a CAGR of XX% during the forecast period. However, the carrier testing market is expected to grow at the highest CAGR of XX% from 2016 to 2021.

Some values in the chart may be randomized. Actual data available on report purchase

By disease, the market is segmented into Alzheimer's, cancer, cystic fibrosis, sickle cell anemia, Duchenne's muscular dystrophy, thalassemia, and Huntingtondisease.

The cancer testing market holds the largest share and is projected to reach USD XX million in 2016 and USD XX billion by 2021. The Alzheimerdisease testing market holds the second largest share and is estimated to reach USD XX million in 2016.

Some values in the chart may be randomized. Actual data available on report purchase

By technology, the market is segmented into cytogenetic testing, molecular testing, and biochemical testing markets.

The molecular testing market holds the largest share, estimated to reach USD XX billion in 2016. However, the cytogenetic testing market is expected to grow at the highest CAGR of XX% during the forecast period.

Some values in the chart may be randomized. Actual data available on report purchase

By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and Latin America.

North America accounted for the highest market share and is estimated to reach USD XX billion in 2016. The market in this region is expected to be valued at USD XX billion by 2021, at a CAGR of XX% from 2016 to 2021. The Asia-Pacific market is growing at a CAGR of XX%.

Some of the key players in the market are:

Transgenomic, Inc.

23 & Me

Sequenom, Inc.

Abbott Molecular

Biocartis SA

Illumina Inc.

Luminex Corporation

Key Deliverables in the Study

Market analysis for the genetic testing market, with region-specific assessments and competition analysis on the global and regional scales.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the genetic testing market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insight about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions where this industry is growing and also to identify the regions that are still untapped.

Table of Contents

1. Introduction

  • 1.1 Study Deliverables
  • 1.2 Market Definition
  • 1.3 Sizing Units
  • 1.4 Base Currency
  • 1.5 Review and Forecast Period Years
  • 1.6 General Study Assumptions

2. Research Methodology

  • 2.1 Introduction
  • 2.2 Analysis Methodology
  • 2.3 Econometric Forecast Model
  • 2.4 Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry trends

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Products and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis

  • 6.1 Market Drivers
    • 6.1.1 Emphasis on Early Disease Detection and Prevention
    • 6.1.2 Growing Demand for Personalized Medicine
    • 6.1.3 Increasing Application of Genetic Testing in Oncology
  • 6.2 Market Restraints
    • 6.2.1 High Costs of Genetic Testing Market
    • 6.2.2 Potentially Adverse Personal or Societal Consequences
  • 6.3 Market Opportunities
    • 6.3.1 Genetic Counseling
    • 6.3.2 Genetic Nursing
  • 6.4 Market Challenges
    • 6.4.1 Lack of Regulation

7. Global Genetic Testing Market Segmentation

  • 7.1 By Type
    • 7.1.1 Carrier Testing
    • 7.1.2 Diagnostic Testing
    • 7.1.3 New Born Screening
    • 7.1.4 Predictive & Presymptomatic Testing
    • 7.1.5 Prenatal Testing
  • 7.2 By Diseases
    • 7.2.1 Alzheimer's Diseases
    • 7.2.2 Cancer
    • 7.2.3 Cystic Fibrosis
    • 7.2.4 Sickle Cell Anemia
    • 7.2.5 Duchenne's Muscular Dystrophy
    • 7.2.6 Thalassemia
    • 7.2.7 Huntington's disease
    • 7.2.8 Others
  • 7.3 By Technology
    • 7.3.1 Cytogenetic testing
    • 7.3.2 Biochemical testing
    • 7.3.3 Molecular Testing
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 USA
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 Germany
      • 7.4.2.2 UK
      • 7.4.2.3 France
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 BENELUX
      • 7.4.2.7 Scandinavia
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China
      • 7.4.3.2 India
      • 7.4.3.3 Japan
      • 7.4.3.4 Australia & New Zealand
      • 7.4.3.5 South Korea
      • 7.4.3.6 Rest of APAC
    • 7.4.4 Middle East & Africa
      • 7.4.4.1 GCC
      • 7.4.4.2 Egypt
      • 7.4.4.3 South Africa
      • 7.4.4.4 Rest of Middle East & Africa
    • 7.4.5 Latin America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest of Latin America

8. Competitive Landscape

  • 8.1 Mergers & Acquisitions
  • 8.2 Agreements, Collaborations & Partnerships
  • 8.3 New Product Launches

9. Company Profiles

  • 9.1 23 & me
  • 9.2 Abbott Molecular
  • 9.3 Ariosa Diagnostics, Inc.
  • 9.4 Biocartis Sa
  • 9.5 Cepheid
  • 9.6 Illumina, Inc
  • 9.7 Luminex Corporation
  • 9.8 Sequenom, Inc
  • 9.9 Transgenomic, Inc

10. Analyst Outlook for Investment Opportunities

11. Future Outlook of the Market

Download Free Sample Now

Back to Top